Log in to your Inderes Free account to see all free content on this page.
Glycorex Transplantation
1.30 SEK
0.00 %
Less than 1K followers
GTAB B
NGM Main Regulated
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Glycorex Transplantation
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 36.1 | 27.0 | 28.2 | 36.1 | 30.0 | 35.2 | 38.8 |
| growth-% | -25.2 % | 4.5 % | 28.1 % | -17.1 % | 17.4 % | 10.5 % | |
| EBITDA | 12.6 | 0.1 | -3.3 | 0.3 | -8.9 | -1.1 | 2.0 |
| EBIT | 7.5 | -7.7 | -11.8 | -8.3 | -30.3 | -10.4 | -7.3 |
| Profit before taxes | 6.9 | -8.1 | -12.2 | -8.5 | -30.4 | -11.0 | -7.8 |
| Net income | 6.9 | -8.0 | -12.2 | -8.6 | -30.4 | -10.9 | -7.7 |
| EPS | 0.10 | -0.11 | -0.17 | -0.12 | -0.41 | -0.15 | -0.10 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | 0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | 34.9 % | 0.4 % | -11.9 % | 0.7 % | -29.8 % | -3.2 % | 5.1 % |
| EBIT-% | 20.8 % | -28.6 % | -42.0 % | -23.0 % | -101.1 % | -29.7 % | -18.9 % |
| ROE | 10.9 % | -8.4 % | -14.8 % | -11.5 % | -68.9 % | -33.0 % | -22.4 % |
| ROI | 8.0 % | -7.1 % | -12.0 % | -8.9 % | -46.1 % | -21.7 % | -15.2 % |
Login required
This content is only available for logged in users